Table 2.
Post-Transplantation Outcomes for Allogeneic HCT to Treat T-ALL
| Outcome | All Patients (n = 208) | Age, yr | Disease Status | Conditioning | TBI Conditioning | Donor Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|||||||||
| ≤35 (n = 91) | >35 (n = 117) | CR1 (n = 88) | ≥CR2 (n = 80) | Relapsed/refractory (n = 38) | MAC (n = 174) | RIC (n = 34) | No TBI (n = 30) | TBI (n = 178) | Identical Sibling (n = 77) | MUD (n = 78) | Alternative Donor (n = 53)* | ||
| OS | |||||||||||||
| 1 yr | 58 (51–65) | 62 (51–72) | 55 (45–63) | 64 (53–73) | 58 (47–68) | 46 (29–61) | 60 (52–67) | 48 (31–64) | 36 (19–53) | 62 (54–69) | 58 (47–69) | 61 (49–71) | 53 (39–66) |
| 5 yr | 34 (27–41) | 47 (36–58) | 22 (14–32) | 44 (32–55) | 33 (22–45) | 14 (5–29) | 36 (28–44) | 24 (10–41) | 12 (2–29) | 37 (29–45) | 34 (23–45) | 34 (21–47) | 34 (20–49) |
| Relapse† | |||||||||||||
| 1 yr | 35 (29–42) | 29 (20–39) | 40 (31–49) | 31 (22–41) | 34 (24–45) | 44 (27–59) | 33 (26–41) | 43 (26–60) | 47 (28–64) | 33 (26–40) | 43 (32–54) | 31 (21–42) | 29 (17–42) |
| 5 yr | 42 (35–49) | 34 (24–44) | 49 (39–58) | 38 (27–49) | 38 (27–49) | 60 (41–75) | 41 (33–49) | 47 (29–64) | 47 (28–64) | 41 (33–49) | 52 (40–62) | 38 (27–50) | 31 (19–45) |
| Relapse mortality† | |||||||||||||
| 1 yr | 24 (18–30) | 21 (13–30) | 26 (19–35) | 20 (12–29) | 22 (13–31) | 35 (20–51) | 22 (16–29) | 31 (16–47) | 34 (17–52) | 22 (16–29) | 30 (20–40) | 18 (11–28) | 23 (12–35) |
| 5 yr | 39 (32–47) | 28 (18–38) | 49 (38–59) | 32 (21–43) | 38 (27–50) | 56 (37–72) | 38 (30–46) | 43 (24–60) | 42 (23–60) | 39 (31–46) | 47 (35–59) | 38 (25–51) | 28 (16–42) |
| NRM† | |||||||||||||
| 1 yr | 18 (13–24) | 17 (10–26) | 19 (12–27) | 16 (9–25) | 20 (12–30) | 19 (8–33) | 18 (12–24) | 21 (9–36) | 30 (15–47) | 16 (11–22) | 12 (6–20) | 21 (13–31) | 24 (13–36) |
| 5 yr | 27 (21–34) | 25 (16–34) | 29 (20–39) | 25 (16–35) | 29 (19–40) | 29 (15–45) | 26 (19–33) | 33 (16–51) | 46 (24–66) | 24 (18–31) | 19 (11–29) | 29 (18–40) | 38 (23–52) |
| Acute GVHD (grade I–IV)† | |||||||||||||
| 3 mo | 55 (48–61) | 56 (45–66) | 54 (44–62) | 58 (47–68) | 59 (48–69) | 39 (24–55) | 53 (45–60) | 64 (44–78) | 59 (38–74) | 54 (47–61) | 49 (38–60) | 58 (47–69) | 58 (43–70) |
| Chronic GVHD† | |||||||||||||
| 1 yr | 28 (22–34) | 28 (19–38) | 28 (20–36) | 32 (23–43) | 22 (13–32) | 31 (16–47) | 25 (19–32) | 41 (23–57) | 33 (17–51) | 27 (20–34) | 31 (21–41) | 31 (20–41) | 19 (9–31) |
Data are outcome probability (%) with 95% CI. MUD indicates matched unrelated donor.
*
Includes mismatched unrelated donor (n = 19), haploidentical donor with post-transplantation cyclophosphamide (n = 10), umbilical cord blood (n = 2 single unit; n = 22 double unit).
†
Cumulative incidence estimates.